GlassScriptPhysician profile
Joanna A Cooper
NPI 1558477018
$7,499.92
in general payments reported to CMS, 2019-2025
27 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,092 · 2020: $239 · 2021: $282 · 2022: $2,502 · 2023: $1,093 · 2024: $816 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,239 · Education: $104 · Travel and Lodging: $42.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.65 |
| Education | $103.75 |
| Travel and Lodging | $42.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $2,045.23 | 2022 | |
| Alexion Pharmaceuticals, INC. | $1,180.03 | 2019-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $814.33 | 2019-2024 | |
| Biogen, INC. | $692.58 | 2019-2024 | Tecfidera, Tysabri |
| Genzyme Corporation | $449.81 | 2019-2024 | |
| Celgene Corporation | $387.15 | 2019 | |
| Horizon Therapeutics Plc | $322.73 | 2022-2023 | Uplizna |
| Abbvie INC. | $256.74 | 2019-2021 | |
| Sk Life Science, INC. | $237.17 | 2022-2023 | Xcopri |
| Genentech USA, INC. | $145.96 | 2019 | |
| Tg Therapeutics, INC. | $139.55 | 2025 | |
| Amgen INC. | $123.74 | 2024 | Uplizna |
| Harmony Biosciences LLC | $121.16 | 2020-2022 | |
| Lilly USA, LLC | $109.39 | 2019 | |
| Emd Serono, INC. | $108.42 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $101.83 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $86.14 | 2023 | Rexulti |
| Jazz Pharmaceuticals INC. | $45.32 | 2020 | |
| Itamar Medical INC | $32.19 | 2025 | Watchpatone |
| Resmed Corp | $28.97 | 2023 | |
| Piramal Critical Care | $22.20 | 2019 | |
| Fisher & Paykel Healthcare INC | $17.99 | 2023 | Fisher & Paykel Healthcare |
| Medtronic USA, INC. | $16.25 | 2020 | |
| Glaxosmithkline, LLC. | $15.04 | 2025 | Trelegy Ellipta |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.